Seegene – World Class Benchmarking
Company: Seegene Incorporated
Bloomberg ticker: 096530 KS
Market cap: US$5,924m
Background: Seegene Incorporated is a Korean company developing, manufacturing and distributing molecular diagnostic reagents. Seegene mainly provides infectious pathogens inspection products, including allergic respiratory pathogens, sexually transmitted diseases (STD) pathogens, human papillomavirus (HPV) and other inspection products, drug resistance inspection products, single nucleotide polymorphisms (SNP) inspection products, as well as somatic mutation cancer inspection products.
World Class Benchmarking of Seegene
- Profitable Growth rank of 1 was same compared to the prior period’s 1st rank
- This is World Class performance compared to 410 medium Health Care companies worldwide
- Profitability rank of 1 was the same as its Growth rank of 1
- Profitability rank of 1 was up compared to the prior period’s 2nd rank
- This is World Class performance compared to peers
- Growth rank of 1 was the same compared to the prior period’s 1st rank
- This is World Class performance compared to peers
DISCLAIMER: This content is for information purposes only. It is not intended to be investment advice. Readers should not consider statements made by the author(s) as formal recommendations and should consult their financial advisor before making any investment decisions. While the information provided is believed to be accurate, it may include errors or inaccuracies. The author(s) cannot be held liable for any actions taken as a result of reading this article.